Abstract
Between the end of 2005 and the beginning of 2006, several new target therapies have been introduced for the treatment of renal cell carcinoma. In this review, we aimed to explore and summarize the main findings of the use of systemic treatment and its effect on surgery in patients with renal cell carcinoma. We identified three different settings: neoadjuvant and adjuvant settings as well as the association of systemic therapy with surgery in the metastatic renal cell carcinoma patients. Neoadjuvant target therapy with tyrosine kinase inhibitor may facilitate the tumor resection and reduce the overall tumor diameter and its complexity. However, most of the evidence is from small phase I or II clinical trials and results are often conflicting without determining a relevant change in the main parameters investigated, such as tumor complexity. In the adjuvant setting, results from pivotal trials investigating the use of tyrosine kinase inhibitors for patients with non-metastatic RCC treated with surgery discourage this practice. Indeed, most of the evidence from single clinical trials and pooled results from meta-analysis failed to find a survival advantage with the use of adjuvant systemic treatment. To date, an improvement of clinical outcomes after systemic targeted therapies could be only found in the setting of cytoreductive nephrectomy. However, the CARMENA and SURTIME trials recently confirmed the evidence against a surgical treatment in patients with mRCC and poor prognosis. In the near future, significant changes may be introduced by the use of immunotherapies.
Keywords: Renal tumor, systemic therapies, immunotherapies, kidney surgery, mRCC, CARMENA and SURTIME.
Graphical Abstract
[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34.
[http://dx.doi.org/10.3322/caac.21551] [PMID: 30620402]
[http://dx.doi.org/10.3322/caac.21551] [PMID: 30620402]
[2]
Bandini M, Smith A, Zaffuto E, et al. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. World J Urol 2018; 36(1): 51-7.
[http://dx.doi.org/10.1007/s00345-017-2093-6] [PMID: 29022072]
[http://dx.doi.org/10.1007/s00345-017-2093-6] [PMID: 29022072]
[3]
Schips L, Zigeuner R, Lipsky K, et al. Do patients with a higher body mass index have a greater risk of advanced-stage renal cell carcinoma? Urology 2003; 62(3): 437-41.
[http://dx.doi.org/10.1016/S0090-4295(03)00380-7] [PMID: 12946742]
[http://dx.doi.org/10.1016/S0090-4295(03)00380-7] [PMID: 12946742]
[4]
Schips L, Dalpiaz O, Lipsky K, et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007; 51(1): 168-73.
[http://dx.doi.org/10.1016/j.eururo.2006.06.026] [PMID: 16844285]
[http://dx.doi.org/10.1016/j.eururo.2006.06.026] [PMID: 16844285]
[5]
Karakiewicz PI, Jeldres C, Suardi N, et al. Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J 2008; 2(6): 610-7.
[http://dx.doi.org/10.5489/cuaj.978] [PMID: 19066680]
[http://dx.doi.org/10.5489/cuaj.978] [PMID: 19066680]
[6]
Bandini M, Marchioni M, Pompe RS, et al. The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. Can Urol Assoc J 2018; 12(7): E325-30.
[http://dx.doi.org/10.5489/cuaj.4854] [PMID: 29603918]
[http://dx.doi.org/10.5489/cuaj.4854] [PMID: 29603918]
[7]
Marchioni M, Martel T, Bandini M, et al. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma. World J Urol 2017; 35(12): 1899-905.
[http://dx.doi.org/10.1007/s00345-017-2082-9] [PMID: 28849260]
[http://dx.doi.org/10.1007/s00345-017-2082-9] [PMID: 28849260]
[8]
Sun M, Abdollah F, Bianchi M, et al. A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. Eur Urol 2011; 60(6): 1152-9.
[http://dx.doi.org/10.1016/j.eururo.2011.07.064] [PMID: 21868147]
[http://dx.doi.org/10.1016/j.eururo.2011.07.064] [PMID: 21868147]
[9]
Cindolo L, Chiodini P, Brookman-May S, et al. Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. BJU Int 2013; 112(5): 578-84.
[http://dx.doi.org/10.1111/j.1464-410X.2012.11670.x] [PMID: 23470199]
[http://dx.doi.org/10.1111/j.1464-410X.2012.11670.x] [PMID: 23470199]
[10]
Karakiewicz PI, Briganti A, Chun FK-H, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25(11): 1316-22.
[http://dx.doi.org/10.1200/JCO.2006.06.1218] [PMID: 17416852]
[http://dx.doi.org/10.1200/JCO.2006.06.1218] [PMID: 17416852]
[11]
Bindayi A, Hamilton ZA, McDonald ML, et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol 2018; 36(1): 31-7.
[http://dx.doi.org/10.1016/j.urolonc.2017.07.015] [PMID: 28802883]
[http://dx.doi.org/10.1016/j.urolonc.2017.07.015] [PMID: 28802883]
[12]
Bandini M, Smith A, Marchioni M, et al. Adjuvant therapies in nonmetastatic Renal-Cell carcinoma: A Review of the literature. Clin Genitourin Cancer 2018; 16(3): 176-83.
[http://dx.doi.org/10.1016/j.clgc.2018.01.003] [PMID: 29449091]
[http://dx.doi.org/10.1016/j.clgc.2018.01.003] [PMID: 29449091]
[13]
Escudier B, Porta C, Schmidinger M, et al. ESMO Guidelines Committee Electronic address: clinicalguidelines@esmo.org. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30(5): 706-20.
[http://dx.doi.org/10.1093/annonc/mdz056] [PMID: 30788497]
[http://dx.doi.org/10.1093/annonc/mdz056] [PMID: 30788497]
[14]
Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic Renal-Cell carcinoma. N Engl J Med 2018; 379(5): 417-27.
[http://dx.doi.org/10.1056/NEJMoa1803675] [PMID: 29860937]
[http://dx.doi.org/10.1056/NEJMoa1803675] [PMID: 29860937]
[15]
Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol 2019; 5(2): 164-70.
[http://dx.doi.org/10.1001/jamaoncol.2018.5543] [PMID: 30543350]
[http://dx.doi.org/10.1001/jamaoncol.2018.5543] [PMID: 30543350]
[16]
Bex A, Albiges L, Ljungberg B, et al. Updated european association of urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma. Eur Urol 2018; 74(6): 805-9.
[http://dx.doi.org/10.1016/j.eururo.2018.08.008] [PMID: 30177291]
[http://dx.doi.org/10.1016/j.eururo.2018.08.008] [PMID: 30177291]
[17]
Marchioni M, Bandini M, Preisser F, et al. Survival after cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: A population-based study. Eur Urol Focus 2019; 5(3): 488-96.
[http://dx.doi.org/10.1016/j.euf.2017.11.012] [PMID: 29229582]
[http://dx.doi.org/10.1016/j.euf.2017.11.012] [PMID: 29229582]
[18]
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017; 376(4): 354-66.
[http://dx.doi.org/10.1056/NEJMra1601333] [PMID: 28121507]
[http://dx.doi.org/10.1056/NEJMra1601333] [PMID: 28121507]
[19]
Marchioni M, Bandini M, Pompe RS, et al. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. Int Urol Nephrol 2017; 49(12): 2143-9.
[http://dx.doi.org/10.1007/s11255-017-1703-y] [PMID: 28932952]
[http://dx.doi.org/10.1007/s11255-017-1703-y] [PMID: 28932952]
[20]
Unverzagt S, Moldenhauer I, Nothacker M, et al. Immunotherapy for metastatic renal cell carcinoma Cochrane Database Syst Rev 2017. 5CD011673
[PMID: 28504837]
[PMID: 28504837]
[21]
Modi PK, Farber NJ, Singer EA. precision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma. Transl Cancer Res 2016; 5(Suppl. 1): S76-80.
[http://dx.doi.org/10.21037/tcr.2016.06.05] [PMID: 27540511]
[http://dx.doi.org/10.21037/tcr.2016.06.05] [PMID: 27540511]
[22]
Lalani AA, McGregor BA, Albiges L, et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions. Eur Urol 2019; 75(1): 100-10.
[http://dx.doi.org/10.1016/j.eururo.2018.10.010] [PMID: 30327274]
[http://dx.doi.org/10.1016/j.eururo.2018.10.010] [PMID: 30327274]
[23]
Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015; 68(2): 267-79.
[http://dx.doi.org/10.1016/j.eururo.2015.02.032] [PMID: 25824720]
[http://dx.doi.org/10.1016/j.eururo.2015.02.032] [PMID: 25824720]
[24]
Meshcheryakova A, Tamandl D, Bajna E, et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One 2014; 9(6)e99008
[http://dx.doi.org/10.1371/journal.pone.0099008] [PMID: 24905750]
[http://dx.doi.org/10.1371/journal.pone.0099008] [PMID: 24905750]
[25]
Mazzone E, Nazzani S, Preisser F, et al. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Cancer Epidemiol 2018; 56: 118-25.
[http://dx.doi.org/10.1016/j.canep.2018.08.006] [PMID: 30173050]
[http://dx.doi.org/10.1016/j.canep.2018.08.006] [PMID: 30173050]
[26]
Marchioni M, Preisser F, Bandini M, et al. Comparison of partial Versus radical nephrectomy effect on other-cause mortality, cancer-specific mortality, and 30-day mortality in patients older than 75 years. Eur Urol Focus 2019; 5(3): 467-73.
[http://dx.doi.org/10.1016/j.euf.2018.01.007] [PMID: 29398456]
[http://dx.doi.org/10.1016/j.euf.2018.01.007] [PMID: 29398456]
[27]
Dey S, Peabody HN, Noyes SL, Lane BR. Neoadjuvant targeted molecular therapy before renal surgery. Urol Clin North Am 2017; 44(2): 289-303.
[http://dx.doi.org/10.1016/j.ucl.2016.12.014] [PMID: 28411920]
[http://dx.doi.org/10.1016/j.ucl.2016.12.014] [PMID: 28411920]
[28]
Assi T, El Rassy E, Farhat F, Kattan J. Overview on the role of preoperative therapy in the management of kidney cancer. Clin Transl Oncol 2019. Epub ahead of print.
[PMID: 31144210]
[PMID: 31144210]
[29]
Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol 2012; 187(5): 1548-54.
[http://dx.doi.org/10.1016/j.juro.2011.12.075] [PMID: 22425095]
[http://dx.doi.org/10.1016/j.juro.2011.12.075] [PMID: 22425095]
[30]
Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010; 184(3): 859-64.
[http://dx.doi.org/10.1016/j.juro.2010.05.041] [PMID: 20643461]
[http://dx.doi.org/10.1016/j.juro.2010.05.041] [PMID: 20643461]
[31]
Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(25): 4076-81.
[http://dx.doi.org/10.1200/JCO.2008.21.3660] [PMID: 19636008]
[http://dx.doi.org/10.1200/JCO.2008.21.3660] [PMID: 19636008]
[32]
Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol 2014; 66(5): 874-80.
[http://dx.doi.org/10.1016/j.eururo.2014.01.035] [PMID: 24560330]
[http://dx.doi.org/10.1016/j.eururo.2014.01.035] [PMID: 24560330]
[33]
Rini BI, Plimack ER, Takagi T, et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015; 194(2): 297-303.
[http://dx.doi.org/10.1016/j.juro.2015.03.096] [PMID: 25813447]
[http://dx.doi.org/10.1016/j.juro.2015.03.096] [PMID: 25813447]
[34]
Pignot G, Loriot Y, Kamat AM, Shariat SF, Plimack ER. Effect of immunotherapy on local treatment of genitourinary malignancies. Eur Urol Oncol 2019; 2(4): 355-64.
[http://dx.doi.org/10.1016/j.euo.2019.01.002] [PMID: 31277773]
[http://dx.doi.org/10.1016/j.euo.2019.01.002] [PMID: 31277773]
[35]
Patel HD, Puligandla M, Shuch BM, et al. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol 2019; 15(15): 1683-95.
[http://dx.doi.org/10.2217/fon-2018-0951] [PMID: 30968729]
[http://dx.doi.org/10.2217/fon-2018-0951] [PMID: 30968729]
[36]
Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387(10032): 2008-16.
[http://dx.doi.org/10.1016/S0140-6736(16)00559-6] [PMID: 26969090]
[http://dx.doi.org/10.1016/S0140-6736(16)00559-6] [PMID: 26969090]
[37]
Ravaud A, Motzer RJ, Pandha HS, et al. S-TRAC Investigators. adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016; 375(23): 2246-54.
[http://dx.doi.org/10.1056/NEJMoa1611406] [PMID: 27718781]
[http://dx.doi.org/10.1056/NEJMoa1611406] [PMID: 27718781]
[38]
Eisen TQG, Frangou E, Smith B, et al. Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL. Ann Oncol 2019; 30: 851-934.
[http://dx.doi.org/10.1093/annonc/mdz394.050]
[http://dx.doi.org/10.1093/annonc/mdz394.050]
[39]
Motzer RJ, Haas NB, Donskov F, et al. PROTECT investigators. randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017; 35(35): 3916-23.
[http://dx.doi.org/10.1200/JCO.2017.73.5324] [PMID: 28902533]
[http://dx.doi.org/10.1200/JCO.2017.73.5324] [PMID: 28902533]
[40]
Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018; 29(12): 2371-8.
[http://dx.doi.org/10.1093/annonc/mdy454] [PMID: 30346481]
[http://dx.doi.org/10.1093/annonc/mdy454] [PMID: 30346481]
[41]
Karakiewicz PI, Zaffuto E, Kapoor A, et al. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Can Urol Assoc J 2018; 12(6): 173-80.
[http://dx.doi.org/10.5489/cuaj.5187] [PMID: 29877179]
[http://dx.doi.org/10.5489/cuaj.5187] [PMID: 29877179]
[42]
Heng DYC, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014; 66(4): 704-10.
[http://dx.doi.org/10.1016/j.eururo.2014.05.034] [PMID: 24931622]
[http://dx.doi.org/10.1016/j.eururo.2014.05.034] [PMID: 24931622]
[43]
Santini D, Santoni M, Conti A, et al. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget 2016; 7(22): 33381-90.
[http://dx.doi.org/10.18632/oncotarget.8302] [PMID: 27027342]
[http://dx.doi.org/10.18632/oncotarget.8302] [PMID: 27027342]
[44]
Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A national cancer data base study. J Clin Oncol 2016; 34(27): 3267-75.
[http://dx.doi.org/10.1200/JCO.2016.66.7931] [PMID: 27325852]
[http://dx.doi.org/10.1200/JCO.2016.66.7931] [PMID: 27325852]
[45]
Motzer RJ, Russo P. Cytoreductive nephrectomy - Patient selection is key. N Engl J Med 2018; 379(5): 481-2.
[http://dx.doi.org/10.1056/NEJMe1806331] [PMID: 29860908]
[http://dx.doi.org/10.1056/NEJMe1806331] [PMID: 29860908]
[46]
Motzer RJ, Tannir NM, McDermott DF, et al. CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378(14): 1277-90.
[http://dx.doi.org/10.1056/NEJMoa1712126] [PMID: 29562145]
[http://dx.doi.org/10.1056/NEJMoa1712126] [PMID: 29562145]
Article Metrics
21